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Although adenosine and its analogues have been assessed in the past as potential drug candidates due 
to the important role of adenosine in physiology, only little is known about their absorption following 
oral administration. In this work, we have studied the oral absorption and disposition pathways of 
cordycepin, an adenosine analogue. In vitro biopharmaceutical properties and in vivo oral absorption 
and disposition of cordycepin were assessed in rats. Despite the fact that numerous studies showed 
efficacy following oral dosing of cordycepin, we found that intact cordycepin was not absorbed 
following oral administration to rats. However, 3′-deoxyinosine, a metabolite of cordycepin previously 
considered to be inactive, was absorbed into the systemic blood circulation. Further investigation 
was performed to study the conversion of 3′-deoxyinosine to cordycepin 5′-triphosphate in vitro 
using macrophage-like RAW264.7 cells. It demonstrated that cordycepin 5′-triphosphate, the active 
metabolite of cordycepin, can be formed not only from cordycepin, but also from 3′-deoxyinosine. 
the novel nucleoside rescue metabolic pathway proposed in this study could be responsible for 
therapeutic effects of adenosine and other analogues of adenosine following oral administration. These 
findings may have importance in understanding the physiology and pathophysiology associated with 
adenosine, as well as drug discovery and development utilising adenosine analogues.
Adenosine is an endogenous purine nucleoside consisting of adenine and ribose and can be phosphorylated 
into mono-, di- and triphosphate forms. Adenosine and its various forms play fundamental roles in numerous 
physiological and pathophysiological processes, ranging from energy transfer, cell signalling to components of 
nucleic acid and coenzymes1. Adenosine itself can induce a wide range of physiological responses of vasodila-
tion, reduction in heart rate, regulation of sympathetic nervous system and antithrombotic effects2. Receptors 
for adenosine are ubiquitously expressed throughout the body and their subtypes (A1, A2A, A2B and A3) possess 
distinct functions in various systems3.
Moreover, the active metabolite of adenosine, adenosine triphosphate (ATP), is a phosphorylated form of 
adenosine which has well-established important biological roles via both intracellular and extracellular mecha-
nisms4. Intracellularly, it is not only associated with cellular metabolism but also with RNA synthesis as a purine 
nucleoside and second messenger system as part of cAMP5. ATP-sensitive potassium ion channels are distributed 
in the cardiac-skeletal and vascular smooth muscles, which then affect the neurotransmission and contraction of 
the cells6. Intracellular concentration of ATP could also determine whether the behaviour of the cells to chem-
otherapeutic treatment would be apoptotic or necrotic7. For chemotherapy, multidrug resistance is a significant 
issue leading to reduced efficacy and it is known that ATP-dependent transporters play key role in the resistance 
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mechanism8. Such variety of biological and pharmacological effects of ATP has led to efforts in development of 
adenosine analogues and their phosphorylated forms as therapeutic agents5,9,10.
However, little is known about the absorption pathways of adenosine and its analogues following oral admin-
istration. In general, it is known that only minimal absorption of adenosine (or its analogues with the adenine 
group) can be achieved due to extensive metabolism during the absorption process in the gastrointestinal tract11–13. 
It has been reported that rapid metabolism (deamination) of the adenine group prevents absorption in its intact 
form and this observation has led to the design of analogues that can avoid this route of degradation14–17.
Cordycepin (3′-deoxyadenosine) is an adenosine analogue which has been studied extensively from mid-20th 
century since its isolation and identification as the main active component of the fungus, Cordyceps militaris18. 
Cordycepin has been reported to have a diverse range of pharmacological effects of which the most well-studied 
areas include anti-inflammation, anti-proliferation and pro-apoptosis19–21. The wide range of potential therapeu-
tic applications of cordycepin has drawn substantial research interest in the compound which resulted in numer-
ous preclinical in vivo efficacy studies in different species22. Reports include claims of efficacy in animal models 
of bone loss23, vascular disorder24, cognitive dysfunction25, sleep disorders26, cancer21,27, neuronal degeneration28, 
hyperlipidaemia29, oxidative stress30, hyperglycaemia31, asthma and lung inflammation32 and viral infection33. 
Indeed, we have recently shown that oral cordycepin is effective in rodent models of osteoarthritis and demon-
strated that it acts as an anti-inflammatory pain killer34. However, there seems to be lack of data on absorption 
and disposition of cordycepin as only extremely limited information can be found in the literature35,36.
As is the case for adenosine and its analogues, oral absorption and bioavailability of cordycepin is not well 
understood, despite multiple in vivo pharmacology studies performed with oral administration and the oral route 
being the intended route of administration for cordycepin23–25,27,29,34,37,38. The information on the oral absorp-
tion processes and the biotransformation of cordycepin is critical in elucidating the exposure-effect relationship, 
especially given that there is strong evidence that cordycepin needs to be converted to cordycepin 5′-triphosphate 
(CordyTP) in order to exert at least some of its pharmacological effects19,39–41.
In this study, we aimed to elucidate absorption and disposition properties of cordycepin, with potential 
wider implications for adenosine and its other analogues. The most important finding of this work was that only 
3′-deoxyinosine, previously considered an inactive metabolite of cordycepin42,43, was absorbed and cordycepin 
was not found in the blood circulation undetectable (detection limit 2 ng/mL) following oral administration. 
We also showed that 3′-deoxyinosine can be converted to CordyTP and has anti-inflammatory effects in tissue 
culture cells. It is likely that similar phenomena also occur with adenosine and its analogues, which would have 
important implications for understanding of their basic biology, as well as understanding of the biotransforma-
tion pathways.
Materials and Methods
Materials. Cordycepin (3′-deoxyadenosine, CAS: 73-03-0) was obtained from Carbosynth Ltd (Berkshire, 
UK). Cordycepin 5′-triphosphate (CordyTP, CAS: 71997-32-5) and 3′-deoxyinosine (CAS: 13146-72-0) were pur-
chased from Santa Cruz Biotechnology (Heidelberg, Germany). Caco-2 cells were purchased from Public Health 
England (Salisbury, UK). Rat plasma was obtained from Sera Laboratories (West Sussex, UK). Human plasma 
was purchased from TCS Biosciences (Buckingham, UK). Pentostatin (deoxycoformycin, CAS: 53910-25-1), 
2′-deoxyadenosine (CAS: 40627-14-3), 2-chloroadenosine (CAS: 146-77-0), foetal bovine serum (FBS), sodium 
taurocholate (NaTc), NaCl, NaOH (pellets), NaH2PO4, KH2PO4, K2HPO4, Dulbecco’s Modified Eagle Medium 
(DMEM), lipopolysaccharide (LPS), S-(4-nitrobenzyl)-6-thioinosine (NBTI), ITu (5-iodotubericidin) and 
NADPH were obtained from Sigma (Gillingham, UK). All solvents were from Fisher Scientific (Leicestershire, 
UK) and were of HPLC grade.
Plasma stability. Stability of cordycepin in plasma was tested using human and rat plasma by following a 
previously reported method with minor modifications44. Cordycepin was spiked into the plasma at 10 µM and the 
samples were incubated in a shaking incubator (Thermo Scientific MaxQ4000, Waltham, MA, USA) at 37 °C and 
shaken at 250 rpm. Samples (100 µL) were withdrawn at predetermined time points. Cordycepin is known to be 
rapidly degraded to 3′-deoxyinosine by the adenosine deaminase enzymes in plasma and pentostatin is often used 
as an inhibitor of this process43,45,46. When pentostatin was tested for stabilisation of cordycepin in plasma, it was 
spiked 5 min prior to spiking of cordycepin. The experiments were performed in triplicates.
Plasma protein binding. Human and rat plasma containing 100 nM of pentostatin were used in the study. 
Cordycepin was spiked into the plasma to give concentrations of 100, 500, 1000 and 5000 ng/mL, and the sam-
ples (300 µL) were incubated in the shaking incubator at 250 rpm and 37 °C for 1 h. Following incubation, 100 µL 
was withdrawn and analysed for Ct. The remaining sample was transferred to a filter device (Amicon Ultra-0.5 
Centrifugal Filter Units, MWCO 3000, Merck Millipore, Cork, Ireland) and was centrifuged at 14,000 g for 10 min 
at room temperature. Filtrate was collected and analysed for Cf. The fraction unbound in plasma (Fub) was calcu-
lated by the equation: Cf/Ct × 100 = Fub. Non-specific binding of cordycepin to the filter device was tested at the 
same concentration range using phosphate buffered saline (PBS) instead of plasma. Experiments were conducted 
in quadruplicates.
Biorelevant solubility. The three biorelevant fluids of fasted state simulated gastric fluid (FaSSGF, pH 1.6), 
fasted state simulated intestinal fluid (FaSSIF, pH 6.5) and fed state simulated intestinal fluid (FeSSIF, pH 5.0) 
were prepared according to previously reported compositions47. The test mixtures containing biorelevant fluids 
and excessive amount of cordycepin were shaken at 250 rpm, 37 °C for 2 h in the shaking incubator. The mixtures 
were then filtered using Costar Spin-X Centrifuge Tubes (Fisher Scientific, Loughborough, UK) at 2400 g for 
5 min. The filtrate was subjected to analysis by HPLC-UV. The experiments were conducted in quadruplicates.
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Caco-2 permeability. Caco-2 permeability assays were conducted following previously reported meth-
ods with 21-day maintenance on the Corning 24-well Transwell® (Fisher Scientific, Loughborough, UK)48. 
Cordycepin was tested at 200 µM with and without presence of pentostatin (10 µM). Both directions of 
apical-to-basolateral and basolateral-to-apical were tested. Permeability was assessed for 120 min with sampling 
every 30 min, and the donor side was sampled after the 120 min to assess remaining concentration of cordycepin 
(the sensitivity limit of the bioanalytical method did not allow to quantify concentration levels of CordyTP in 
these samples). The experiments were conducted in triplicates.
Liver microsomal stability. Human and rat liver microsomes were used in the experiment following previ-
ously reported methods49,50. Microsomes were used at 0.5 mg protein/mL and cordycepin was tested at 1 µM. Four 
groups were tested for both species of microsomes: 1) with NADPH (1 mM) and with pentostatin (10 µM); 2) with 
NADPH and without pentostatin; 3) without NADPH and with pentostatin; and 4) without NADPH and without 
pentostatin. The reaction mixture was incubated in the shaking incubator at 37 °C for 30 min with sampling every 
10 min. The results of intrinsic clearance and the fraction that escapes hepatic metabolism (by both well-stirred 
and parallel-tube models) were calculated by previously reported equations and physiological parameters50–52. 
The experiments were performed in triplicates.
In vitro experiments using macrophage cells. RAW 264.7 mouse macrophage cells were cultured in 
DMEM supplemented with 10% FBS. Prior to experiments, cells were washed with PBS and cells were maintained 
in DMEM with 0.5% FBS or 10% FBS for 24 h. LPS was added at 1 µg/mL, 1 h before compound treatment, when 
needed. When the cells were analysed for concentration levels of cordycepin, 3′-deoxyinosine and CordyTP, the 
cells were washed twice with PBS. The cells were then treated with methanol and mixed vigorously before the 
mixture was harvested. The mixture was filtered using filter tubes mentioned above and the filtrate was analysed 
by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). For determination of relative 
mRNA levels, RNA was isolated from the lysates using an RNA isolation kit, following manufacturer’s protocol 
(Promega, Madison, WI, cat no. Z6012). RNA was reverse transcribed to cDNA using SuperScript™ III reverse 
transcriptase (Invitrogen, Carlsbad, CA). Quantitative polymerase chain reaction (qPCR), was performed with 
Qiagen Rotor-Gene Q qPCR machine (Qiagen, Hilden, Germany) using Promega SYBR Green GoTaq® qPCR 
master mix (Promega). Supplementary Information 1 shows the list of qPCR primers used.
In vivo pharmacokinetic experiments. Protocols for the animal experiments in this study were reviewed 
and approved by the University of Nottingham Ethical Review Committee in accordance with the Animals 
[Scientific Procedures] Act 1986. Four male Sprague Dawley rats (Charles River Laboratories, UK) of 300–350 g 
body weight were used. The animals were housed in the Bio Support Unit, University of Nottingham at controlled 
temperature, 12 h light/dark cycle and free access to food and water. The animals were allowed to acclimatise for 
at least six days prior to any procedures.
Prior to pharmacokinetic studies, jugular vein cannulation surgery was performed under general anaesthesia 
(<3% isoflurane inhalation) for blood sampling or intravenous drug administration. Following two nights of 
recovery from surgery, the animals were intravenously or orally administered with the PBS-based formulation 
(5.5 mg/mL cordycepin) developed in a previously reported study22. The dose was 8 or 20 mg/kg for intrave-
nous administration and 8 or 80 mg/kg for oral administration. Blood samples (approx. 0.2 mL) were collected 
at predetermined time points into Eppendorf tubes pretreated with pentostatin (10 µM). When whole blood was 
analysed, an aliquot was withdrawn immediately after mixing with the pretreated pentostatin. Otherwise, the 
mixture was centrifuged (3000 g, 10 min) to obtain plasma and samples were stored within the storage conditions 
tested prior to analysis.
Bioanalytical procedures for determination of concentrations. Samples from studies of plasma sta-
bility, protein binding, biorelevant solubility and liver microsomal stability were subjected to liquid-liquid extrac-
tion and HPLC-UV analysis. To 100 µL of sample, internal standard (2′-deoxyadenosine) was spiked at 10 µg/mL 
and 300 µL of 0.1 M NaOH was added. Extraction solvent (3 mL) of ethyl acetate-isopropyl alcohol (85:15, v/v) 
was added and vortex-mixed for 10 min. Samples were then centrifuged at 1160 g for 5 min and the supernatant 
was transferred and dried under N2 gas. Dried samples were reconstituted with 100 uL of deionised distilled 
water (DDW) and 40 µL was injected into the HPLC-UV. The HPLC-UV setup was adopted from a validated 
method22 with addition of a gradient scheme to elute the impurities from samples. Waters Alliance 2695 module 
with Waters 996 PDA detector was used for the HPLC-UV system with Capcell Pak C18 3 µm, 4.6 × 150 mm as 
the stationary phase. Mobile phase was a mixture of acetonitrile (A) and DDW (B) at flow rate 0.8 mL/min with a 
gradient scheme of the following: 0–9 min, B 94%; 9–14 min, B decreased to 20%; 14–24 min, B 20%; 24–26 min, 
B increased to 94%; and 26–35 min, B 94%. Calibration curves were constructed at a range of 10 – 20000 ng/mL 
and chromatograms were obtained at 259 nm of wavelength.
Samples from Caco-2 permeability, in vitro determination of CordyTP formation and in vivo experiments 
were subjected to protein precipitation followed by LC-MS/MS analysis. To 50 µL of rat plasma sample, 150 µL 
of internal standard solution (1.67 µg/mL 2-chloroadenosine in methanol) was added. The samples were then 
vortex-mixed for 10 s and were centrifuged for 3 min at 17949 g. Supernatant (20 µL) was collected and diluted 
10-fold with DDW before injection into the LC-MS/MS for analysis of cordycepin and 3′-deoxyinosine. For 
analysis of CordyTP, the supernatant was filtered using filter tubes mentioned above and injected without dilu-
tion. Tissue samples were homogenised using Bullet Blender Gold (Next Advance, Inc., Troy, NY) in methanol 
(1:3 w/v) and centrifuged for 3 min at 17949 g. The supernatant was filtered and injected for analysis of CordyTP or 
diluted 10-fold with DDW for analysis of cordycepin and 3′-deoxyinosine. The LC-MS/MS system was a API4000 
QTrap (AB Sciex, Warrington, UK) equipped with HPLC setup of SCL10Avp controller, LC10ADvp pump and 
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SILHTC autosampler (Shimadzu, Milton Keynes, UK). Three different methods were utilised for each compound 
and multiple reaction monitoring parameters of the MS/MS conditions are shown in Table 1. The HPLC con-
ditions including stationary phases and specific mass spectrometry parameters are shown in Supplementary 
Information 2. The LC-MS/MS method for cordycepin was fully validated in terms of accuracy, precision, sensi-
tivity, selectivity, linearity and sample storage stability in accordance with the Guidance for Industry, Bioanalytical 
Method Validation, (2018) published by the US FDA (refer to Supplementary Information 3 for validation pro-
cedures and results)53.
Data analysis. Data are presented as mean ± standard deviation (SD). A two-tailed unpaired t-test was 
applied for assessment of statistical significance of differences between two groups. For three or more groups, the 
statistical significance was assessed by application of a one-way ANOVA followed by Tukey’s multiple compari-
sons test. A p-value lower than 0.05 was deemed statistically significant. Statistical analyses were conducted using 
GraphPad Prism version 7.01 (GraphPad Software, Inc., La Jolla, CA, USA). Pharmacokinetic parameters were 
obtained by non-compartmental analysis using Phoenix WinNonlin 6.3 software (Pharsight, Mountain View, 
CA, USA).
Results
In vitro biopharmaceutical assessment of cordycepin. The stability of cordycepin was tested in rat 
and human plasma (Fig. 1a), which showed comparable ex vivo stability half-lives (t1/2) between the two spe-
cies (rat: t1/2 = 25.0 ± 0.7 min; human: t1/2 = 25.8 ± 4.0 min). The inhibition of this metabolism by pentostatin was 
tested at a wide range of concentrations using rat plasma during 1 h incubation (Fig. 1b). Pentostatin was shown 
to be a potent inhibitor of the enzyme, exhibiting stabilising effect of cordycepin from at 1 nM. This set of results 
served as the basis for using pentostatin as stabiliser of cordycepin in the samples during or following in vitro and 
in vivo experiments.
Binding of cordycepin (stabilised by pentostatin) to plasma proteins was tested in vitro in rat and human 
plasma using the ultrafiltration method (Fig. 1c). The fraction unbound (Fub) in plasma was > 80% and did not 
differ across the concentration range tested and between species. Such high Fub could be expected considering the 
low lipophilicity of cordycepin (log P = −0.41, ACD/Labs, Toronto, Canada). The non-specific binding of cord-
ycepin to the ultrafiltration tubes was tested with PBS and was found to be negligible (2–3%), which is consistent 
with tests using other filtration devices22.
Solubility of cordycepin was tested in the biorelevant media of FaSSGF, FaSSIF and FeSSIF (Fig. 1d). The 
solubilities in the three biorelevant fluids were higher than previously reported solubility in water (5.0 ± 0.1 mg/
mL)22. Since nucleoside analogues, including cordycepin, are weak bases, the solubility was significantly higher in 
FaSSGF compared to the two simulated intestinal fluids. Solubility in FaSSIF and FeSSIF was comparable, indi-
cating that food effect on oral absorption of cordycepin would be minimal.
Permeability was tested in vitro using Caco-2 cells to predict intestinal absorption of cordycepin (Fig. 1e–g). 
Caco-2 cells mimic the gastrointestinal environment by forming villi-like shapes and expressing brush bor-
der enzymes54,55. Time-dependent permeation of cordycepin itself (Fig. 1e) could only be obtained in the 
presence of pentostatin. When tested without pentostatin, cordycepin permeation was not detected in either 
apical-to-basolateral or basolateral-to-apical directions suggesting a rapid metabolism under the tested condi-
tions. Accordingly, only the permeation of 3′-deoxyinosine, the metabolite of cordycepin, was detected when 
cordycepin was tested in the absence of pentostatin (Fig. 1f). Our results (Fig. 1e–f) suggest that cordycepin was 
most probably metabolised by adenosine deaminase enzyme secreted by Caco-2 cells during the permeation. 
This was further confirmed by analysis of donor chambers for remaining concentrations of cordycepin at the 
end of the permeability experiments (at 120 min). We found that cordycepin was significantly degraded when it 
was applied to the apical side without pentostatin (Fig. 1g). When cordycepin was applied with pentostatin to the 
apical side or without pentostatin to the basolateral side, the concentration of cordycepin remained stable. This is 
most likely because Caco-2 cells are oriented with villi and enzymes secretion to the apical side and therefore the 
metabolising enzymes are expected to be present in the apical side only. These data suggest that cordycepin will 
likely be completely deaminated before it has a chance to be absorbed in the intestine. The bioanalytical method 
used in this study was not able to quantify levels of CordyTP in these samples. This could be because of two plau-
sible reasons: 1) CordyTP produced by the Caco-2 cells could have been rapidly metabolised by ecto-nucleotidase 
enzymes upon release into the extracellular environment, which would also apply for plasma samples56; 2) Caco-2 
cells may not be able to produce CordyTP at all.
Compound
ESI 
mode Q1 (m/z) Q3 (m/z) DP (V) EP (V)
CE 
(eV)
CXP 
(eV)
Cordycepin + 252.2 136.0 41 10 23 10
3′-Deoxyinosine + 253.2 137.1 66 10 27 10
CordyTP − 490.0 158.8 −100 −10 −42 −7
2-chloroadenosine
(internal standard) + 302.1 170.1 61 10 27 12
Table 1. Multiple reaction monitoring parameters of the LC-MS/MS conditions of cordycepin, 3′-deoxyinosine 
and CordyTP. ESI, electrospray ionisation; DP, declustering potential; EP, entrance potential; CE, collision 
energy; CXP, collision cell exit potential.
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Rat and human liver microsomes were used to test the microsomal stability of cordycepin for prediction of 
hepatic metabolism (Table 2). Intrinsic clearance (CLint) was calculated for the rate of hepatic metabolism and the 
fraction that escapes hepatic metabolism (Fh) was obtained from the CLint. The presence of NADPH did not affect 
the CLint in both species. It indicates that the CYP-catalysed reactions are not the main contributors in metabo-
lism of cordycepin, since the activity of these enzymes would depend on the presence of the cofactor, NADPH51. 
On the other hand, the CLint was substantially affected by the presence of pentostatin which demonstrated that 
the degradation by adenosine deaminase is predominant in hepatic metabolism. The CLint was significantly higher 
in rat liver microsome compared with that of human, which is consistent with previous observations for many 
other compounds57. The Fh calculated from CLint was 10–13% by the well-stirred model and close to 0% by the 
parallel-tube model51. Therefore, it was predicted that bioavailability of cordycepin could potentially be heavily 
affected by the hepatic first-pass metabolic loss following oral administration.
Figure 1. In vitro biopharmaceutical assessment of cordycepin (mean ± SD). (a) Time-dependent degradation 
of cordycepin in rat and human plasma (n = 4). (b) Stabilisation effect of pentostatin on cordycepin tested in rat 
plasma at different concentrations of pentostatin (1 pM – 10 µM) (n = 4). **p < 0.01 compared to control group 
(without pentostatin). (c) Plasma protein binding results of cordycepin in rat and human plasma presented as 
fraction unbound (Fub) in plasma (n = 4). (d) Biorelevant solubility of cordycepin tested in fasted state simulated 
gastric fluid (FaSSGF), fasted state simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid 
(FeSSIF) (n = 4). **p < 0.01. (e) Permeability of cordycepin tested using Caco-2 cells with co-administration 
of pentostatin at both apical-to-basolateral (A to B) and basolateral-to-apical (B to A) directions (n = 3). (f) 
Permeation of 3′-deoxyinosine when Caco-2 cells are treated with cordycepin without co-administration of 
pentostatin. In this case, permeation of cordycepin was not detected (n = 3). (g) Cordycepin concentrations 
analysed before and after the permeability experiment in the donor chambers (n = 3). **p < 0.01.
Rat liver microsome Human liver microsome
NADPH + + − − + + − −
Pentostatin + − + − + − + −
CLint (mL/min/kg) ND 392.2 ± 31.3 ND 390.0 ± 51.4 ND 181.4 ± 13.9 ND 179.1 ± 5.3
Fh (%), well-stirred modela ND 12.4 ± 0.9 ND 12.5 ± 1.5 ND 10.3 ± 0.7 ND 10.4 ± 0.3
Fh (%), parallel-tube modela ND 0.1 ± 0.0 ND 0.1 ± 0.1 ND 0.0 ± 0.0 ND 0.0 ± 0.0
Table 2. Liver microsomal stability of cordycepin tested with rat and human liver microsomes (mean ± SD, 
n = 3). NADPH, Nicotinamide adenine dinucleotide phosphate; CLint, intrinsic clearance; Fh, fraction that 
escapes hepatic metabolism; ND, not determined. The CLint and Fh for groups indicated ND could not be 
calculated as cordycepin was stable for the time period tested. aWell-stirred and parallel-tube models were 
adopted from ref.51
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In vivo pharmacokinetic experiments. Cordycepin was administered intravenously (8 and 20 mg/kg) 
and orally (8 and 80 mg/kg) to rats for assessment of in vivo pharmacokinetics of cordycepin and its metabolite, 
3′-deoxyinosine (Fig. 2). Intravenous administration profiles of cordycepin showed that cordycepin was rapidly 
distributed in the system followed by a fluctuating plasma elimination phase (Fig. 2a). Despite such an unusual 
disposition pattern with fluctuating plasma elimination phase following intravenous bolus administration, a very 
similar phenomenon has been previously reported for another nucleoside analogue, which suggests that this 
could be a class nucleoside-type compounds behaviour58 (Fig. 2a). Partitioning of cordycepin to erythrocytes 
or other blood cells was proposed as a possible explanation for the unusual elimination phase and therefore 
concentration in whole blood was also measured for 20 mg/kg dose group (explained further in Discussion sec-
tion). However, the blood/plasma ratio turned out to be only 0.68 ± 0.27 and similar unusual disposition pattern 
was also observed for concentrations of cordycepin in whole blood. Interestingly, the profiles of the metabolite 
3′-deoxyinosine following intravenous bolus of cordycepin, exhibited a typical plasma concentration-time profile 
following intravenous administration (Fig. 2b). Moreover, the profiles of 3′-deoxyinosine in plasma and whole 
blood following administration of cordycepin (20 mg/kg) were superimposable.
More importantly, when cordycepin was administered to rats orally, it was not detected in plasma at all, at any 
time point, even with the dose as high as 80 mg/kg. Interestingly however, the metabolite 3′-deoxyinosine was 
found to be absorbed systemically instead and the plasma concentration-time profiles depicted in Fig. 2c demon-
strated high concentrations of 3′-deoxyinosine following oral administration of cordycepin.
Pharmacokinetic parameters obtained for cordycepin and 3′-deoxyinosine following administration of cord-
ycepin are shown in Tables 3 and 4, respectively. The cordycepin concentration extrapolated to time zero (C0) 
following intravenous administration was increased 13.8-fold when the dose was increased from 8 to 20 mg/
kg (Table 3). Nevertheless, the area under the concentration-time curve (AUC) only increased by 1.18-fold. 
Pharmacokinetics of 3′-deoxyinosine following intravenous bolus also did not show dose-linearity (Table 4). 
Following intravenous administration, the clearance (CL) was found to increase with the dose (between 8 
and 20 mg/kg), indicating saturation of the elimination mechanisms. Likewise, the AUC/Dose following oral 
administration showed a decrease when dose was increased from 8 to 80 mg/kg, which suggests a saturable 
Figure 2. In vivo pharmacokinetic profiles of cordycepin and its metabolite, 3′-deoxyinosine, following 
administration of cordycepin in rats (mean ± SD). (a) Profiles of cordycepin following intravenous 
administration of cordycepin at 8 or 20 mg/kg (n = 4). (b) Profiles of 3′-deoxyinosine following intravenous 
administration of cordycepin at 8 or 20 mg/kg (n = 4). (c) Profiles of 3′-deoxyinosine following oral 
administration of cordycepin at 8 or 80 mg/kg (n = 5).
Route of administration Intravenous
Dose (mg/kg) 8 20
C0 (ng/mL) 890 ± 576 12298 ± 8844
AUC0→t (ng·h/mL) 196 ± 94 232 ± 106
AUC0→t/Dose (ng·h·kg/mL/mg) 25 ± 12 12 ± 5
CL (L/h/kg) 103 ± 52 91 ± 41
Table 3. Pharmacokinetic parameters of cordycepin following intravenous administration of cordycepin. C0, 
concentration extrapolated to time zero; AUC0→t, area under the concentration-time curve from time zero to 
the last time point observed; CL, clearance.
7Scientific RepoRtS |         (2019) 9:15760  | https://doi.org/10.1038/s41598-019-52254-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
absorption process. Therefore, the bioavailability of 3′-deoxyinosine achievable by oral administration of cordy-
cepin (Foral) was calculated based on the AUC values obtained at lower dose level of 8 mg/kg only (36.8 ± 11.3%). 
Pharmacokinetic profiles and parameters of cordycepin itself following oral administration of cordycepin could 
not be calculated as no cordycepin was detected after oral administration despite the very sensitive analytical 
methodology utilised in this work (limit of quantification = 2 ng/mL).
Macrophage derived cells can generate CordyTP from 3′-deoxyinosine. It is intriguing that no 
intact cordycepin was detected in plasma in in vivo studies in rats following oral administration, apparently 
contradicting numerous studies reporting efficacy of cordycepin when given orally, including our own on osteo-
arthritis pain23–25,27,29,34,37,38. Although 3′-deoxyinosine has been previously considered an inactive metabolite, its 
potential contribution towards efficacy needed further investigation in light of these unexpected pharmacokinetic 
findings (explained further in Discussion section). Firstly, we sought to confirm that cordycepin needs to be 
converted intracellularly into CordyTP in order to exert its therapeutic effect. Macrophage-like RAW264.7 cells 
have been previously reported to be sensitive to cordycepin59. The cells were treated with adenosine transporter 
inhibitor (NBTI), adenosine kinase inhibitor (ITu) or DMSO prior to cordycepin treatment. The results show that 
NBTI or ITu treatments inhibit the inhibitory effect of cordycepin on expression of inflammatory genes (Fig. 3a). 
It indicates that indeed cordycepin needs to be transported into the cell and also be phosphorylated intracellularly 
to have its therapeutic effects which is in agreement with previous reports19,39–41. Secondly, it was tested whether 
3′-deoxyinosine can manifest the similar therapeutic effects of cordycepin on inflammatory gene expression. 
RAW264.7 cells were treated with cordycepin or 3′-deoxyinosine prior to stimulation with LPS for inflammatory 
response. Although 3′-deoxyinosine is not as potent as cordycepin, it also suppressed expression of inflammatory 
genes (Fig. 3b).
Our data in Fig. 3a support the idea that CordyTP is the substance responsible for the pharmacologi-
cal effects related to cordycepin19,39–41. Therefore, the possibility of RAW264.7 cells generating CordyTP from 
3′-deoxyinosine was tested. We found that the macrophages were indeed able to produce CordyTP from 
3′-deoxyinosine (although at an approximately 10-fold lower ratio compared to CordyTP generated from cord-
ycepin) (Fig. 4). These results indicate that 3′-deoxyinosine, a compound which was previously considered an 
inactive metabolite, could have a major role in therapeutic effects following oral administration of cordycepin.
Discussion
With the various physiological roles played by adenosine, extensive research has been conducted into devel-
opment of adenosine analogues as selective and efficient therapeutic agents. However, there has been lack of 
information on pharmacokinetics of adenosine and its analogues following oral administration. In this study, 
we aimed to characterise absorption and disposition properties of one of important adenosine analogues, cord-
ycepin, which would propose potential application to adenosine itself and its other analogues. Up to date, only 
few studies have been conducted on pharmacokinetics of cordycepin35,36. Wei et al. reported a medicinal chem-
istry study where prodrugs of cordycepin were synthesised and evaluated following oral administration in mice. 
However there is minimal information available for the analytical method used and the actual concentrations 
reported are not all within the calibration curve range, which inevitably would have affected the pharmacokinetic 
evaluations35. Tsai et al. conducted pharmacokinetic studies in rats but the information is rather insufficient 
as unfortunately blood samples were taken sparsely only in the 30–90 min time range following intravenous 
administration36.
In this study, we utilised a fully validated and sensitive bioanalytical method to elucidate the in vivo plasma 
pharmacokinetic profiles of cordycepin. Cordycepin showed rapid disposition following intravenous adminis-
tration (Fig. 2a). In vitro biopharmaceutical assessment showed that cordycepin has low protein binding (Fig. 1) 
with high hepatic (Table 2) and plasma clearance (Fig. 1), which is consistent with such rapid disposition kinetics 
in vivo. However, the multiple peaks pattern in the elimination phase was unexpected and unusual. Interestingly, 
Route of administration Intravenous Oral
Dose (mg/kg) 8 20 8 80
C0 or Cmax (ng/mL) 5729 ± 1633 16347 ± 3871 202 ± 98 1280 ± 267
AUCinf (ng·h/mL) 723 ± 177 2736 ± 720 297 ± 69 1707 ± 555
AUCinf/Dose (ng·h·kg/mL/mg)a 90 ± 22 137 ± 36 37 ± 9 21 ± 7
Tmax (h) — — 0.25 0.5
t1/2 (h) 0.29 ± 0.09 0.80 ± 0.29 1.11 ± 0.39 0.85 ± 0.36
CL (L/h/kg)b 11.5 ± 2.7 7.8 ± 2.2 — —
Vss (L/kg) 2.8 ± 0.3 3.0 ± 0.7 — —
Foral (%)c — — 36.8 ± 11.3 —
Table 4. Pharmacokinetic parameters of 3′-deoxyinosine following intravenous and oral administration of 
cordycepin. Cmax, maximum concentration observed, AUCinf, area under the concentration-time curve from 
time zero to infinity; Tmax, time of maximum concentration observed; t1/2, elimination half-life; Vss, volume 
of distribution at steady state; Foral, oral bioavailability of 3′-deoxyinosine achievable by administration of 
cordycepin. Refer to Table 3 for abbreviation of other parameters. aSignificant difference between AUCinf/Dose 
of 8 and 80 mg/kg oral administration groups was found (p < 0.05). bSignificant difference between CL of 8 and 
20 mg/kg intravenous administration groups was found (p < 0.05).
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this irregular pattern has been previously reported for another adenosine analogue, 3-deazaneplanocin A58. 
Excessive partitioning of cordycepin to blood cells was initially proposed as a possible cause of this phenom-
enon. However, simultaneous determination of cordycepin concentrations in whole blood and plasma showed 
that the blood-to-plasma ratio was in fact <1. Moreover, the multiple peaks were also observed in whole blood 
Figure 3. Repression effect on inflammatory gene expression. (a) NBTI or ITu treatment prior to cordycepin 
treatment suppresses effect of cordycepin. RAW264.7 cells were treated with 10 µM NBTI, 100 nM ITu or DMSO 
(Ctrl, control) 15 min prior to cordycepin treatment. The cells were stimulated with LPS 1 h after cordycepin treatment 
(mean ± SD, n = 3). **p < 0.01; ***p < 0.001 compared to DMSO treatment (labelled as Ctrl). (b) 3′-deoxyinosine 
exerts same repression effect as cordycepin, although to a lesser degree. RAW264.7 cells were treated with 20 µM 
cordycepin, 20 µM 3′-deoxyinosine (3DI) or DMSO (Ctrl, control) for 1 h prior to LPS stimulation (mean ± SD, 
n = 3). **p < 0.01; ***p < 0.001 compared to without compound treatment (labelled as LPS).
Figure 4. Levels of cordycepin, 3′-deoxyinosine and CordyTP found following in vitro treatment with 
cordycepin or 3′-deoxyinosine. RAW264.7 cells maintained in 0.5 or 10% (foetal bovine serum (FBS) conditions 
were treated with cordycepin or 3′-deoxyinosine at 20 µM for 6 h (mean ± SD, n = 3).
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concentration profiles (Fig. 2a). Enterohepatic recirculation was ruled out as a possibility because no cordycepin 
was found to be orally absorbed. Therefore, ours as well as previous findings for this unusual disposition profile 
following intravenous administration of adenosine analogue58 do not fully explain this phenomenon. Although 
this was not the main focus in the current work, this unusual disposition profile warrants further investigation 
in future studies.
The main finding in this work was that no cordycepin was found in the systemic circulation following oral 
administration despite relatively high administered dose. Biorelevant solubility results indicated that solubility 
of cordycepin in the gastrointestinal environment is high and therefore is highly unlikely to be the reason for 
lack of oral bioavailability (Fig. 1). On the other hand, the apparent permeability coefficient (Papp) calculated 
from Fig. 1a was 0.11 ± 0.01 × 10−6 cm/s (A to B), indicating that cordycepin is a compound with poor per-
meability48. It should also be noted that this Papp could only be obtained when pentostatin was used to inhibit 
enzymatic activity of adenosine deaminase. In the absence of pentostatin, cordycepin was not detected in 
the receiver compartment probably due to the rapid deamination process. This observation is in line with 
a previous report in which an increasing amount of inosine was found when adenosine was perfused into 
the gastrointestinal tract12. Low permeability data, taken together with the high hepatic first-pass effect pre-
dicted from liver microsomal studies (Table 2), could explain the lack of oral bioavailability of cordycepin. The 
abovementioned study on 3-deazaneplanocin A tested different routes of administration and they also did not 
observe any meaningful plasma concentration-time profile following oral administration58. However, there are 
a number of in vivo studies reporting substantial efficacy of cordycepin for different indications following oral 
administration23–25,27,29,34,37,38.
In order to understand the apparent contradiction of the lack of oral bioavailability of cordycepin and mul-
tiple reports of its therapeutic effects following oral administration, we searched for possible metabolites that 
could have been potentially absorbed following oral administration of cordycepin. We found that 3′-deoxyinosine 
appeared at high levels in the systemic circulation in vivo following oral administration of cordycepin in rats. 
As a result, the bioavailability of 3′-deoxyinosine following oral administration of cordycepin was as high as 
36.8%. (Fig. 2c). Indeed, the in vitro Caco-2 permeability assay also revealed that when cordycepin is applied, 
3′-deoxyinosine permeated the cell monolayer instead of cordycepin (Fig. 1f). This in vitro experiment suggests 
that cordycepin is rapidly metabolised during the absorption processes and intact cordycepin could not penetrate 
the intestinal wall unless it was co-treated with pentostatin. In addition, the Papp of 3′-deoxyinosine was still quite 
low (approximately 0.2 × 10−6 cm/s (A to B)), while the Foral of 3′-deoxyinosine was 36.8% (Table 4). This indicates 
possibility of involvement of active transport in the gut that may facilitate absorption of 3′-deoxyinosine.
Although 3′-deoxyinosine is bioavailable, it has been suggested previously that 3′-deoxyinosine is an inactive 
metabolite, while CordyTP is the active moiety responsible for therapeutic effects of cordycepin39,42,43. In this 
study, we showed that 3′-deoxyinosine suppresses expression of the same genes as cordycepin does, although 
with lower potency (Fig. 3b). Nevertheless, since 3′-deoxyinosine has been reported previously as an inactive 
metabolite42,43, we hypothesised that some cells may have a metabolic pathway that can convert 3′-deoxyinosine 
to CordyTP. In order to test this hypothesis, we assessed the ability of a macrophage cell line to generate CordyTP 
from 3′-deoxyinosine in vitro. Although at significantly lower levels compared with cordycepin treatment, the 
application of 3′-deoxyinosine indeed resulted in detectable levels of CordyTP (Fig. 4). This difference in lev-
els of generated CordyTP is consistent with studies reporting enhanced effect of cordycepin when pentostatin 
Figure 5. Proposed metabolic pathways of cordycepin. The thicker arrows indicate the novel nucleoside rescue 
metabolic pathway proposed in this study.
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is co-administered42,43,46. This is because pentostatin inhibits metabolism of cordycepin and therefore greater 
amounts of cordycepin can be taken up by the cells to convert it into CordyTP. Further studies will be needed to 
investigate whether the conversion of 3′-deoxyinosine to CordyTP in vivo could produce levels of CordyTP which 
are high enough to exert the same pharmacodynamic effects.
A pathway for conversion of 3′-deoxyinosine into CordyTP which could explain the phenomenon is suggested 
in Fig. 5. In fact, there have been previous reports of this conversion, although the research was conducted mostly 
with parasites rather than mammalian cells60,61. Nevertheless, the conversion of inosine and its analogues to their 
respective adenosine triphosphate analogues has been also demonstrated using mammalian cells62. A similar 
pathway had been proposed for another adenosine analogue, 2′,3′-dideoxyadenosine, but the authors have not 
confirmed the proposed mechanism experimentally13. It is important to investigate in the future work which 
enzymes are responsible for the conversion of 3′-deoxyinosine to CordyTP. If this nucleoside recovery pathway is 
cell-type specific, the in vivo effects of cordycepin observed in multiple previous studies may be due to effects on 
a limited number of cell types and tissues.
In conclusion, in this work we have demonstrated that despite numerous previous studies showing therapeu-
tic effects of cordycepin following oral administration, it is in fact not orally bioavailable. However, a metabolite 
previously considered inactive (3′-deoxyinosine) has significant bioavailability following oral administration of 
cordycepin. Moreover, we have shown that 3′-deoxyinosine could be converted to the active moiety CordyTP in 
mammalian cells, and therefore could be responsible for therapeutic effects of cordycepin when it is administered 
orally. These findings provide an important insight into the mechanisms of therapeutic effects of cordycepin. 
Moreover, this metabolic pathway could play an important role in activity of adenosine and other adenosine ana-
logue drugs. The metabolised products (i.e. the apparently inactive metabolite of cordycepin, 3′-deoxyinosine) are 
available in the systemic circulation instead and can return to the phosphorylation pathway of their parent form 
as shown in this study. If drug candidates can be designed with this pathway in mind, extensive derivatisation that 
focuses on bypassing the metabolism and delivering the intact form could be avoided.
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